NON-CONTROLLING INTEREST |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Noncontrolling Interest [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Noncontrolling Interest Disclosure [Text Block] |
NOTE 10 – NON-CONTROLLING INTEREST
On November 7, 2018, the Company formed ViralClear for the purpose to pursue additional applications of the PURE EP™ signal processing technology outside of electrophysiology and subsequently in 2020 was repurposed to develop a broad-spectrum anti-viral agent that had potential against the COVID-19 virus. In late 2020, ViralClear again was repurposed back to pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology.
As of June 30, 2021 and December 31, 2020, the Company had a majority interest in ViralClear of 69.95% and 70.21%, respectively.
A reconciliation of the ViralClear Pharmaceuticals, Inc. non-controlling loss attributable to the Company:
Net loss attributable to the non-controlling interest for the three months ended June 30, 2021 (000’s):
Net loss attributable to the non-controlling interest for the three months ended June 30, 2020 (000’s):
Net loss attributable to the non-controlling interest for the six months ended June 30, 2021 (000’s):
Net loss attributable to the non-controlling interest for the six months ended June 30, 2020 (000’s):
The following table summarizes the changes in non-controlling interest for the six months ended June 30, 2021 (000’s):
|